2013_ASCO的临床试验对临床实践的影响.pptVIP

研究名称 分组 患者数 PFS/TTP(m) P值 OS(m) P值 Brodowicz GEM vs BSC 138 vs 68 6.6 vs 5.0 0.001 13.0 vs 11.0 0.195 66 vs 33(KPS80) 25.3 vs 11.0 HR=2.1 Belani Paclitaxel vs observation 65 vs 65 38 w vs 29 w 0.124 75 w vs 60 w 0.243 Belani 2010 GEM vs BSC 128 vs 127 7.4 vs 7.7 0.575 8.0 vs 9.3 0.838 Perol GEM vs observation 154 vs 155 3.8*vs1.9 0.0001 12.1 vs. 10.8 0.3867 ECOG 4599 Bev+PC vs. PC 433 vs. 417 6.2 vs. 4.5 0.001 12.3 vs. 10.3 0.003 FLEX NP+ Cetuximab vs NP 557 vs. 568 4.8 vs. 4.8 0.39 11.3 vs. 10.1 0.044 Paramount Pem vs. observation 359 vs. 180 4.1 vs. 2.8* 0.00006 16.9 vs. 14.0 0.0191 AVAPERL